Chris Kilbee appointed Group director of UBM Pharma Portfolio
pharmafile | January 10, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | CPhI, UBM pharma, amsterdam
Amsterdam: CPhI, part of UBM Live, has announced the appointment of Chris Kilbee to the role of Group director of the UBM Pharma Portfolio.
Kilbee will be responsible for driving the firm’s portfolio globally including an increased emphasis on digital and content.
Central to the role is responsibility for the strategic development and delivery of its event brands CPhI, ICSE, Inno-Pack and P-MEC, that take place in Europe and worldwide.
An experienced business leader who has worked across a number of different parts of UBM, Kilbee was most recently running a media and events business based in London.
Kilbee said: “I am delighted to be taking on this position and overseeing the Pharma portfolio at UBM Live. It is our vision to widen CPhI’s pharma portfolio across new and diverse geographies and platforms where we see opportunities emerging, delivering new services that help to connect the pharma community.”
Related Content
Pharmapack Predictions 2025: the Good the Bad and…. the Donald 2.0
Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a …
Pharma prepares for CDMO growth in 2025 as CPHI Milan reports record attendance
13 December 2024 – Amsterdam, the Netherlands – CPHI Milan – the world’s largest pharma …

Stelis, Strides and Steriscience merge to form new CDMO
The CDMO launched earlier this year at the CPHI conference in Milan. The merger is …






